TF and glioma: PAMAM-PEG conjugated with transferrin [69], chlorotoxin [70], or Angiopep-2 [71] have allowed increased distribution of therapeutics in glioma tissue after systemic delivery in mice or rats in comparison to treatment with PAMAM-PEG alone, demonstrating the clinical potential of ligand-conjugated dendrimers for intravenous delivery of gene therapy for glioma treatment.